uniQure Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

uniQure şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.04%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.04%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: UQ1 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: UQ1 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

uniQure Piyasaya Karşı Temettü Getirisi

UQ1 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (UQ1)	n/a
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.9%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (UQ1) (3 yıla kadar)	0%

Önemli Temettü: UQ1 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, UQ1 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: UQ1 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: UQ1 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

uniQure Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Third quarter 2024 earnings released: US$0.91 loss per share (vs US$1.88 loss in 3Q 2023)

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.16 loss per share (vs US$1.44 loss in 2Q 2023)

Uniqure N.V. Announces Executive Changes

Now 22% overvalued

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$1.36 loss per share (vs US$1.63 loss in 1Q 2023)

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold €163k worth of stock

Full year 2023 earnings released: US$6.47 loss per share (vs US$2.71 loss in FY 2022)

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Now 25% undervalued after recent price drop

Third quarter 2023 earnings released: US$1.88 loss per share (vs US$1.02 loss in 3Q 2022)

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Second quarter 2023 earnings released: US$1.44 loss per share (vs US$0.84 loss in 2Q 2022)

uniQure N.V. Announces Executive Changes

New major risk - Share price stability

First quarter 2023 earnings released: US$1.63 loss per share (vs US$1.00 loss in 1Q 2022)

CEO & Executive Director recently sold €465k worth of stock

Full year 2022 earnings released: US$2.71 loss per share (vs US$7.17 profit in FY 2021)

CEO & Executive Director recently sold €142k worth of stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Third quarter 2022 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$8.68 profit in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Chief Operating Officer recently sold €95k worth of stock

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

First quarter 2022 earnings released: US$1.00 loss per share (vs US$0.91 loss in 1Q 2021)

uniQure N.V., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CEO & Executive Director recently sold €152k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

CEO & Executive Director recently sold €175k worth of stock

Investor sentiment deteriorated over the past week

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.79 loss per share (vs US$1.21 loss in 3Q 2020)

President of Research & Development recently sold €271k worth of stock

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$8.68 (vs US$0.96 loss in 2Q 2020)

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. (NasdaqGS:QURE) entered into a definitive agreement to acquire Corlieve Therapeutics SAS for €250 million.

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure N.V. Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Forecast to breakeven in 2021

No longer forecast to breakeven

uniQure N.V. Presents Hope-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Antibodies to Aav5 Vector

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.63 loss in 1Q 2020)

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

CEO, CFO & Executive Director recently sold €152k worth of stock

Full year 2020 earnings released: US$2.81 loss per share (vs US$3.11 loss in FY 2019)

Revenue misses expectations

New 90-day low: €28.63

uniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Chief Accounting Officer recently sold €261k worth of stock

New 90-day low: €30.00

uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program

Uniqure N.V. Announces the Late-Breaking Presentation of Initial Data from Its Pivotal, Phase Iii Hope-B Gene Therapy Trial of E 2 Tranacogene D 4Ezaparvovec